A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.

Trial Profile

A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms SOFIA
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Jan 2012 Actual patient number (31) added as reported by ClinicalTrials.gov (Extension trial: NCT01054222).
    • 23 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov (Extension trial: NCT01054222).
    • 23 Jan 2012 Status of the extension trial is completed (Extension trial: NCT01054222).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top